Current state of biologicals in the management of systemic vasculitis

Annals of the New York Academy of Sciences

Volumn 1110, Issue , 2007, Pages 261-270

  Lamprecht, Peter ^a   Till, Andreas ^b   Steinmann, Jörg ^b   Aries, Peer M ^a   Gross, Wolfgang L ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Antineutrophil cytoplasmic autoantibody (ANCA); Systemic vasculitides; Wegener's granulomatosis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADD ON THERAPY; ANCA ASSOCIATED VASCULITIS; AUTOIMMUNITY; B LYMPHOCYTE; BIOLOGICAL ACTIVITY; BIOLOGICAL THERAPY; CELL DAMAGE; CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; DEGRANULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EARLY INTERVENTION; ENDOTHELIUM CELL; EX VIVO STUDY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOID TISSUE; NONHUMAN; PATHOGENICITY; PROGNOSIS; REMISSION; SINGLE DRUG DOSE; SYSTEMIC VASCULITIS; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

EID: 35748961418     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1423.028     Document Type: Conference Paper

References (40)

1. GROSS, W.L. 2004. Immunopathology and new therapeutic considerations in ANCA-associated vasculitides. Autoimmun. Rev. 3(Suppl.1): S47-S48.
2. JENNETTE, J.C. & R.J. FALK. 1997. Small vessel vasculitis. N. Engl. J. Med. 337: 1512-1523.
3. CSERNOK, E., P. LAMPRECHT & W.L. GROSS. 2006. Diagnostic significance of ANCA in vasculitis. Nat. Clin. Pract. Rheum.
4. NÖLLE, B., U. SPECKS, J. LÜDEMANN, et al. 1989. Anticytoplasmic autoantibodies: their immundiagnostic value in Wegener's granulomatosis. Ann. Int. Med. 111: 28-40.
5. HEERINGA, P., D. HUUGEN & J.W. COHEN TERVAERT. 2005. Anti-neutrophil cytoplasmic autoantibodies and leukocyte-endothelial interactions: a sticky connection? Trends Immunol. 26: 561-564.
6. HARPER, L. & C.O.S. SAVAGE. 2000. Pathogenesis of ANCA-ssociated systemic vasculitis. J. Pathol. 190: 349-359.
7. XIAO, H., P. HEERINGA, P. HU, et al. 2002. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110: 955-963.
8. HUUGEN, D., H. XIAO, A. VAN ESCH, et al. 2005. Aggravation of antimyeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am. J. Pathol. 167: 47-58.
9. LITTLE, M.A., L. SMYTH, R. YADAV, et al. 2005. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 106: 2050-2058.
10. LITTLE, M.A., G. BHANGAL, L. SMYTH, et al. 2006. Therapeutic effect of anti-TNF-α antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 17: 160-169.
11. PFISTER, H., M. OLLERT, L.F. FRÖHLICH, et al. 2004. Antineutrophil cytoplasmic autoantibodies (ANCA) against the murine homolog of proteinase 3 (Wegener's autoantigen) are pathogenic in vivo. Blood 104: 1411-1418.
12. BACON, P.A. 2005. The spectrum of Wegener's granulomatosis and disease relapse. N. Engl. J. Med. 352: 330-332.
13. HELLMICH, B., E. CSERNOK & W.L. GROSS. 2005. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann.N.Y. Acad. Sci. 1051: 121-131.
14. SARRAF, P. & M. SNELLER. 2005. Pathogenesis of Wegener's granulomatosis: Current concepts. Expert. Rev. Mol. Med. 7: 1-19.
15. JAGIELLO, P., W.L. GROSS & J. EPPLEN. 2005. Complex genetics of Wegener's granulomatosis. Autoimmun. Rev. 4: 42-47.
16. POPA, E.R., C.A. STEGEMAN, C.G.M. KALLENBERG & J.W. COHEN TERVAERT. 2002. Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res. 4: 77-79.
17. PENDERGRAFT, W.F. III, G.A. PRESTON, R.S. SHAH, et al. 2004. Autoimmunity is triggered by cPR-3 (105-201), a protein complementary to human autoantigen proteinase 3. Nat. Med. 10: 72-79.
18. FIENBERG, R. 1989. A morphologic and immunohistologic study of the evolution of the necrotizing palisading granuloma of pathergic (Wegener's) granulomatosis. Semin. Resp. Med. 10: 126-132.
19. KRADIN, R.L. & E.J. MARK. 2002. Case records of the Massachusetts General Hospital: Weekly clinicopathological exercises. Case 18-2002, a 48-year-old man with a cough and bloody sputum. N. Engl. J. Med. 346: 1892-1899.
20. KOMOCSI, A., P. LAMPRECHT, E. CSERNOK, et al. 2002. Peripheral blood and granuloma CD4+CD28- T-cells are a major source of IFN-g and TNF-α in Wegener's granulomatosis. Am. J. Pathol. 160: 1717-1724.
21. VOSWINKEL, J., A. MUELLER, J.A. KRAEMER, et al. 2006. B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann. Rheum. Dis. 65: 859-864.
22. CSERNOK, E., M. AI, W.L. GROSS, et al. 2006. Wegener's autoantigen induces maturation of dendritic cells and licences them for Th1 priming via the protease-activated receptor-2 pathway. Blood 107: 4440-4448.
23. STONE, J.H., M.L. UHLFELDER, D.B. HELLMANN, et al. 2001. Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-months open-label trial to evaluate safety. Arthritis Rheum. 44: 1149-1154.
24. THE WEGENER'S GRANULOMATOSIS ETANERCEPT (WGET) RESEARCH GROUP. 2005. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352: 351-361.
25. LAMPRECHT, P., G. KUMANOVICS, A. MUELLER, et al. 2002. Elevated monocytic IL-12 and TNF-α production in Wegener's granulomatosis is normalized by cyclophosphamide and corticosteroid therapy. Clin. Exp. Immunol. 128: 181-186.
26. HELLMICH, B., P. LAMPRECHT & W.L. GROSS. 2006. Advances in the treatment of Wegener's granulomatosis. Curr. Opin. Rheumatol. 18: 25-32.
27. TARGAN, S.R., S.B. HANAUER, S.J. van DEVENTER, et al. 1997. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N. Engl. J. Med. 337: 1029-1035.
28. SANDBORN, W.J., B.G. FEAGAN, S.B. HANAUER, et al. 2001. Etanercept (p75 soluble tumor necrosis factor receptor:Fc fusion protein) for active Crohn's disease: a randomized double-blind, placebo-controlled trial. Gastroenterology 121: 1088-1094.
29. VAN DEN BRANDE, J.M., H. BRAAT, G.R. VAN DEN BRINK, et al. 2003. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124: 1774-1785.
30. WAETZIG, G.H. & S. SCHREIBER. 2004. Mechanisms of infliximab: the reverse side of a drug effect. Inflamm. Bowel Dis. 10(Suppl 1): S38-43.
31. WAETZIG, G.H., P. ROSENSTIEL, S. NIKOLAUS, et al. 2003. Differential p38 mitogen-activated protein kinase target phosphorylation in responders and nonresponders to infliximab. Gastroenterology 125: 633-634.
32. WAETZIG, G.H., P. ROSENSTIEL, A. ARLT, et al. 2005. Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-beta1. FASEB J 19: 91-93.
33. MUKHTYAR, C. & R. LUQMANI. 2005. Current state of tumour necrosis factor a blockade in Wegener's granulomatosis. Ann. Rheum. Dis. 64(Suppl.4): 31-36.
34. GAUSE, A., O. ARBACH & P. LAMPRECHT. 2003. Treatment of primary systemic vasculitis with TNF-α antagonists. Z. Rheumatol. 62: 228-234.
35. KEOGH, K., M. WYLAM, J. STONE & U. SPECKS. 2005. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52: 262-268.
36. SNELLER, M.C. 2005. Rituximab and Wegener's granulomatosis: Are B cells a target in vasculitis treatment? Arthritis Rheum. 52: 1-5.
37. ARIES, P.M., B. HELLMICH, J. VOSWINKEL, et al. 2006. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann. Rheum. Dis. 65: 853-858.
38. SMITH, K.G.C., R.B. JONES, S.M. BURNS & D.R.W. JAYNE. 2006. Long-term comparison of rituximab treatment for refractory systemic lupus erythmeatosus and vasculitis. Arthritis Rheum. 54: 2970-2982.
39. NOVICK, D., M. RUBINSTEIN, T. AZAM, et al. 2006. Proteinase 3 is an IL-32 binding protein. Proc. Natl. Acad. Sci. USA 103: 3316-3321.
40. LAMPRECHT, P., E. CSERNOK & W.L. GROSS. 2006. Effector memory T-cells as driving force of granuloma formation and autoimmunity in Wegener's granulomatosis. J. Intern. Med. 260: 187-191.